Comparison of thyroglobulin antibody interference in first-and second-generation thyroglobulin immunoassays

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 6, 2011, Pages 1025-1027

  Giovanella, Luca ^a   Ceriani, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

differentiated thyroid cancer; interferences; thyroglobulin; thyroglobulin antibodies

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE;

ABLATION THERAPY; ANALYTICAL EQUIPMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FALSE NEGATIVE RESULT; FOLLOW UP; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERUM; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ANTIBODIES; ARTIFACTS; BLOOD CHEMICAL ANALYSIS; HUMANS; IMMUNOASSAY; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 79958245535     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.155     Document Type: Article

References (12)

1. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
2. Smallridge RC, Meek S, Morgan MA, Gates GS, Fox TP, Grabe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimu-lated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7. (Pubitemid 46075007)
3. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004;89:3702-4. (Pubitemid 39071459)
4. Giovanella L. False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. Eur J Nucl Med Mol Imaging 2009;36:326-7.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
6. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-95. (Pubitemid 47037347)
7. Spencer CA, Fatemi S, Singer PA, Nicoloff JT, LoPresti JS. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stim-ulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010;20:587-95.
8. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7. (Pubitemid 28496379)
9. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S. LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90: 5566-75. (Pubitemid 41415459)
10. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067-73.
11. La'ulu S, Slev PR, Roberts WL. Performance characteristics of 5 automated thyroglobulin autoantibody and thyroid peroxidase autoantibody assays. Clin Chim Acta 2007;376:88-95. (Pubitemid 44880984)
12. Grebe SK. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Expert Rev Endocrinol Metab 2009;4:25-43.